Omeros CorpNASDAQ:OMER
- LAST PRICE3.9200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.5300/ 1
- Ask / Lots4.1900/ 10
- Open / Previous Close3.9700 / 3.9200
- Day Range
- 52 Week Range
- Volume139,417
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OMER |
|---|---|---|
| 09:32 ET | 1322 | 3.97 |
| 09:34 ET | 200 | 3.915 |
| 09:36 ET | 100 | 3.89 |
| 09:38 ET | 5624 | 3.96 |
| 09:39 ET | 1800 | 3.99 |
| 09:41 ET | 100 | 3.9775 |
| 09:45 ET | 100 | 3.975 |
| 09:50 ET | 300 | 3.97 |
| 09:52 ET | 400 | 3.97 |
| 09:56 ET | 2174 | 3.98 |
| 09:57 ET | 1345 | 3.985 |
| 10:01 ET | 1759 | 3.98 |
| 10:06 ET | 8482 | 3.985 |
| 10:10 ET | 1500 | 3.98 |
| 10:14 ET | 1800 | 3.98 |
| 10:15 ET | 200 | 3.965 |
| 10:28 ET | 854 | 4 |
| 10:32 ET | 300 | 3.99 |
| 10:33 ET | 200 | 4 |
| 10:35 ET | 1000 | 4 |
| 10:42 ET | 1014 | 4.01 |
| 10:44 ET | 176 | 4.008 |
| 10:48 ET | 10048 | 4.015 |
| 10:50 ET | 150 | 4.0137 |
| 10:51 ET | 200 | 4 |
| 10:53 ET | 300 | 4 |
| 10:57 ET | 100 | 4 |
| 11:02 ET | 1500 | 4 |
| 11:04 ET | 800 | 4 |
| 11:06 ET | 1295 | 4 |
| 11:09 ET | 300 | 4.01 |
| 11:18 ET | 100 | 4.01 |
| 11:20 ET | 250 | 4.01 |
| 11:22 ET | 200 | 4 |
| 11:26 ET | 400 | 4 |
| 11:27 ET | 179 | 4 |
| 11:29 ET | 511 | 3.99 |
| 11:31 ET | 100 | 3.985 |
| 11:40 ET | 800 | 3.95 |
| 11:42 ET | 100 | 3.96 |
| 11:44 ET | 110 | 3.9517 |
| 11:45 ET | 1000 | 3.965 |
| 11:47 ET | 596 | 3.96 |
| 11:49 ET | 700 | 3.99 |
| 12:02 ET | 200 | 3.99 |
| 12:09 ET | 200 | 3.98 |
| 12:12 ET | 100 | 3.98 |
| 12:16 ET | 800 | 3.965 |
| 12:18 ET | 100 | 3.97 |
| 12:20 ET | 5070 | 3.94 |
| 12:23 ET | 100 | 3.94 |
| 12:32 ET | 346 | 3.9159 |
| 12:34 ET | 255 | 3.93 |
| 12:43 ET | 100 | 3.92 |
| 12:48 ET | 500 | 3.9 |
| 12:50 ET | 200 | 3.9 |
| 12:59 ET | 100 | 3.895 |
| 01:06 ET | 300 | 3.9 |
| 01:10 ET | 500 | 3.89 |
| 01:19 ET | 600 | 3.87 |
| 01:28 ET | 300 | 3.8799 |
| 01:30 ET | 1350 | 3.9 |
| 01:37 ET | 100 | 3.905 |
| 01:39 ET | 879 | 3.895 |
| 01:51 ET | 100 | 3.9 |
| 01:53 ET | 672 | 3.905 |
| 02:04 ET | 100 | 3.9 |
| 02:09 ET | 100 | 3.8998 |
| 02:11 ET | 100 | 3.9 |
| 02:15 ET | 600 | 3.895 |
| 02:18 ET | 705 | 3.92 |
| 02:20 ET | 100 | 3.92 |
| 02:26 ET | 100 | 3.915 |
| 02:27 ET | 300 | 3.895 |
| 02:29 ET | 100 | 3.895 |
| 02:31 ET | 400 | 3.885 |
| 02:33 ET | 1488 | 3.87 |
| 02:38 ET | 100 | 3.875 |
| 02:40 ET | 250 | 3.87 |
| 02:44 ET | 2400 | 3.87 |
| 02:45 ET | 400 | 3.88 |
| 02:47 ET | 100 | 3.89 |
| 02:54 ET | 1040 | 3.88 |
| 02:56 ET | 400 | 3.875 |
| 03:00 ET | 2281 | 3.88 |
| 03:02 ET | 500 | 3.87 |
| 03:03 ET | 375 | 3.87 |
| 03:09 ET | 100 | 3.87 |
| 03:12 ET | 1301 | 3.86 |
| 03:14 ET | 1800 | 3.86 |
| 03:25 ET | 2000 | 3.86 |
| 03:32 ET | 100 | 3.865 |
| 03:34 ET | 3083 | 3.87 |
| 03:36 ET | 3246 | 3.88 |
| 03:38 ET | 334 | 3.885 |
| 03:39 ET | 200 | 3.885 |
| 03:41 ET | 1812 | 3.885 |
| 03:43 ET | 1000 | 3.8891 |
| 03:45 ET | 1137 | 3.895 |
| 03:48 ET | 300 | 3.9 |
| 03:50 ET | 924 | 3.905 |
| 03:54 ET | 1070 | 3.905 |
| 03:56 ET | 200 | 3.9 |
| 03:57 ET | 1282 | 3.93 |
| 03:59 ET | 24070 | 3.92 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Omeros Corp | 227.2M | -1.2x | --- |
Kyverna Therapeutics Inc | 226.5M | 0.0x | --- |
Trevi Therapeutics Inc | 228.7M | -8.6x | --- |
Candel Therapeutics Inc | 224.9M | -4.2x | --- |
Acrivon Therapeutics Inc | 224.9M | -2.6x | --- |
Pyxis Oncology Inc | 221.1M | -2.9x | --- |
Company Information
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Contact Information
- Headquarters
- 201 Elliott Avenue WestSEATTLE, WA, United States 98119
- Phone
- 206-676-5000
- Fax
- 206-676-5005
Executives
- Chairman of the Board, President, Chief Executive Officer
- Gregory Demopulos
- Chief Accounting Officer, Vice President - Finance, Treasurer
- David Borges
- Vice President - Science, Chief Scientific Officer
- George Gaitanaris
- Vice President, General Counsel, Secretary
- Peter Cancelmo
- Vice President - Human Resources
- Peter Williams
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $227.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.48 |
EPS | $-3.32 |
Book Value | $-0.41 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
